INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 56 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2013. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $1,100,871 | +5.4% | 81,971 | -3.0% | 0.00% | – |
| Q4 2022 | $1,044,807 | -16.2% | 84,463 | -5.5% | 0.00% | – |
| Q3 2022 | $1,247,000 | -4.4% | 89,412 | -5.3% | 0.00% | – |
| Q2 2022 | $1,304,000 | -15.1% | 94,376 | 0.0% | 0.00% | – |
| Q1 2022 | $1,536,000 | -1.3% | 94,376 | -1.3% | 0.00% | – |
| Q4 2021 | $1,557,000 | -95.4% | 95,605 | -65.0% | 0.00% | -100.0% |
| Q4 2019 | $33,817,000 | +2080.3% | 272,893 | +1067.6% | 0.01% | – |
| Q3 2019 | $1,551,000 | +10.9% | 23,372 | +32.9% | 0.00% | – |
| Q2 2019 | $1,399,000 | +153.0% | 17,584 | +255.3% | 0.00% | – |
| Q1 2019 | $553,000 | +13.3% | 4,949 | -14.9% | 0.00% | – |
| Q2 2018 | $488,000 | +28.8% | 5,816 | +263.5% | 0.00% | – |
| Q3 2014 | $379,000 | -15.8% | 1,600 | -15.8% | 0.00% | – |
| Q2 2014 | $450,000 | -86.4% | 1,900 | -81.0% | 0.00% | -100.0% |
| Q1 2014 | $3,303,000 | -9.1% | 10,015 | -87.6% | 0.00% | 0.0% |
| Q2 2013 | $3,632,000 | – | 81,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Chicago Capital Management, LLC | 185,781 | $4,611,565 | 12.16% |
| Samsara BioCapital, LLC | 640,688 | $11,878,356 | 3.64% |
| ALPINE ASSOCIATES MANAGEMENT INC. | 2,203,295 | $40,849,089 | 2.14% |
| Versor Investments LP | 378,480 | $7,017,019 | 1.42% |
| Magnetar Financial LLC | 2,407,209 | $44,629,655 | 1.14% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,077,893 | $38,524,136 | 0.85% |
| Fort Baker Capital Management LP | 430,600 | $7,983,324 | 0.74% |
| EHP Funds Inc. | 84,210 | $1,561,253 | 0.73% |
| Terrapin Asset Management, LLC | 30,000 | $556,200 | 0.63% |
| AQR Arbitrage LLC | 734,970 | $13,626,344 | 0.61% |